Přejít k obsahu
Global sound
After Market

After Market

Imugene forges ahead with VAXINIA trial targeting solid tumours

· 9 min · Epizoda 11

Poznámky k epizodě

Clinical-stage immuno-oncology biotech Imugene has been making significant strides in the development of therapies targeting a range of cancers. In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA).

Web: after-market.simplecast.com

Živě, poslední hodina: 13 306 skladeb na 6 043 stanicích v 139 zemích

Objevte svět prostřednictvím rádia

Další způsoby objevování (7)

Slyšeli jste něco pěkného? Uložte si to, nebo to otevřete rovnou ve Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
Perron FMPokračovat v poslechu